More Amplia Therapeutics Ltd. news
Amplia Therapeutics Ltd.ASX: ATX

App 4E - Preliminary Final Report YE 31 March 2021

May 31, 2021 at 1:07 AM EDT · Issued by Amplia Therapeutics Ltd.

Filed with ASX · May 31, 2021 at 1:07 AM EDT

On 6ix: 6ix.com/news/app-4e-preliminary-final-report-ye-31-march-2021

Amplia Therapeutics Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Amplia Therapeutics Ltd. on 6ix

Earlier from Amplia Therapeutics

  • Proposed issue of Securities - ATXMay 4, 2021
  • Amplia Announces $3.8m Share PlacementMay 3, 2021
  • Preclinical Data Support Developmnt AMP945 Pancreatic CancerApr 27, 2021
  • Quarterly Report and Shareholder UpdateApr 27, 2021
  • ATX FAK Inhibitors Reduce Fibrosis in Animal Model of NASHApr 19, 2021

Later from Amplia Therapeutics

  • AMP945 Improves Survival in Pacnreatic Cancer ModelJun 1, 2021
  • Amplia and Garvan Enter Into Collaboration AgreementJun 27, 2021
  • Results from Successful Phase 1 Clinical Trial of AMP945Jul 20, 2021
  • Quarterly Activities and Cashflow Reports and PresentationJul 27, 2021
  • AGM - Chief Executive Officers PresentatioinAug 27, 2021
All Amplia Therapeutics news releases↗

Follow Amplia Therapeutics into a list and get an email when it puts out news.

Follow Amplia Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer